Table 2 Medical characteristics according to geographical settings
Characteristics | Urban n (%) | Rural n (%) | Total n (%) | |
|---|---|---|---|---|
Baseline CD4 count | ≥ 500 cell/mm3 | 59 (31.7) | 16 (55.2) | 75 (34.9) |
< 500 cell/mm3 | 127 (68.3) | 13 (44.8) | 140 (65.1) | |
WHO clinical stage | stage I/II | 179 (68.8) | 43 (71.7) | 222 (69.4) |
Stage III/IV | 81 (31.2) | 17 (29.3) | 98 (30.6) | |
Endpoint CD4 count | ≥ 500 cell/mm3 | 49 (75.4) | 5 (50) | 54 (72.0) |
< 500 cell/mm3 | 16 (24.6) | 5 (50) | 21 (28.0) | |
Retained in care | Yes | 294 (88.6) | 52 (85.2) | 346 (88.9) |
No | 36 (11.4) | 8 (14.8) | 47 (12.0) | |
Loss to follow up | Yes | 28 (8.5) | 8 (13.3) | 36 (9.3) |
No | 300 (91.5) | 52 (86.7) | 352 (90.7) | |
Anemia at start | Yes | 129 (94.2) | 24 (77.4) | 153 (91.1) |
No | 8 (5.8) | 7 (22.6) | 15 (8.9) | |
Opportunistic infection | Yes | 42 (12.5) | 5 (8.3) | 47 (11.9) |
No | 293 (87.5) | 55 (61.7) | 348 (88.1) | |
Cotrimoxazole prophylaxis | Yes | 293 (92.4) | 55 (90.2) | 348 (92.1) |
No | 24 (7.6) | 6 (9.8) | 30 (7.9) | |
Treatment regimen | First linea | 306 (93.9) | 52 (85.2) | 358 (92.5) |
Second lineb | 20 (6.1) | 9 (14.8) | 29 (8.5) | |
Exposure to cNVP prophylaxis for dPMTCT | Yes | 13 (7.6) | 7 (1.8) | 20 (9.5) |
No | 158 92.4) | 33 (98.2) | 191 (90.5) | |
Mode of transmission | Vertical | 236 (97.5) | 29 (74.4) | 265 (94.3) |
Horizontal | 6 (2.5) | 10 (25.6) | 16 (5.7) |